{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:42Z","timestamp":1790803302257,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["FS\/14\/55\/30806"],"award-info":[{"award-number":["FS\/14\/55\/30806"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011103","name":"Sixth Framework Programme","doi-asserted-by":"publisher","award":["LSH-2005-2.1.1.1"],"award-info":[{"award-number":["LSH-2005-2.1.1.1"]}],"id":[{"id":"10.13039\/100011103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.atherosclerosis.2022.06.1020","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T01:51:16Z","timestamp":1656121876000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study"],"prefix":"10.1016","volume":"354","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9802-8241","authenticated-orcid":false,"given":"Robert","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Hammami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sherliker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Valdes-Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma C.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib1","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib2","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib3","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"Lipoprotein(a), diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib5","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2011.12.033","article-title":"Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction","volume":"59","author":"Leibundgut","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbalip.2010.03.009","article-title":"Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts","volume":"1801","author":"Edelstein","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11239-015-1292-5","article-title":"Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction","volume":"42","author":"DeFilippis","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijcard.2020.05.008","article-title":"Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes","volume":"315","author":"Schnitzler","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"26","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","article-title":"Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the national heart, lung, and blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000807","article-title":"Plasma cytokines and risk of coronary heart disease in the PROCARDIS study","volume":"5","author":"Clarke","year":"2018","journal-title":"Open Heart"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib17","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jacc.2012.08.979","article-title":"Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.06.1020_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacc.2016.10.057","article-title":"SPARCL trial investigators. Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack","volume":"69","author":"Byun","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"The LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/sim.1485","article-title":"Improved estimates of floating absolute risk","volume":"23","author":"Plummer","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.ATV.10.2.240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0038-1646308","article-title":"Plasminogen levels in healthy volunteers: influence of age, sex, smoking and oral contraceptives","volume":"68","author":"Tait","year":"1992","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib25","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","volume":"110","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib26","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.carrev.2011.08.001","article-title":"The role of oxidised phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularisation","volume":"13","author":"Fefer","year":"2012","journal-title":"Cardiovasc. Revascularization Med."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","article-title":"Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans","volume":"63","author":"Ravandi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidised phospholipids on apolipoprotein B100 and lipoprotein (a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib30","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016318","article-title":"Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events","volume":"9","author":"Willeit","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib34","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.06.1020_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022013193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:49:05Z","timestamp":1758156545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022013193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S0021915022013193"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1020","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}